Placebo, NaCl 0.9%

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Dengue FeverDengue Hemorrhagic Fever

Phase 2

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

CompletedNCT02623725

Sanofi Pasteur, a Sanofi CompanyDengue Fever, Dengue Hemorrhagic Fever

Start: 2016-04-14End: 2018-10-28Updated: 2022-03-24

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

CompletedNCT02824198

Sanofi Pasteur, a Sanofi CompanyDengue Fever, Dengue Hemorrhagic Fever

Start: 2016-07-01End: 2019-01-18Updated: 2022-03-24

Related Papers

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

Human Vaccines & Immunotherapeutics2021-02-245 citations

Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4–5 Years Earlier in Latin America

The Pediatric Infectious Disease Journal2020-09-126 citations

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series

Human Vaccines & Immunotherapeutics2019-08-2911 citations